E
SYRE icon

Ergoteles’s Spyre Therapeutics SYRE Stock Holding History

Ergoteles’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-589
Closed -$6.62K – 1742
2022
Q4 		$6.62K Buy
+589
New +$10.6K ﹤0.01% 1380
2022
Q3 		– Sell
-5,888
Closed -$74K – 1976
2022
Q2 		$74K Buy
+5,888
New +$206K ﹤0.01% 1541
2021
Q3 		– Sell
-1,364
Closed -$237K – 1649
2021
Q2 		$237K Buy
+1,364
New +$248K 0.01% 1196

Other funds holding SYRE

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Ergoteles's SYRE Position: Q1 2023 in Review

Ergoteles sold out of Spyre Therapeutics (SYRE) in Q1 2023, closing a stake of 589 shares — an estimated $6.62K sold.

Ergoteles first reported a position in SYRE in Q2 2021 and held it in 3 quarters. The position peaked at $237K in Q2 2021. 44 funds tracked by Wall St. Rank hold SYRE as of Q1 2023.

  • Ergoteles reported no remaining Spyre Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 589 Spyre Therapeutics shares in Q1 2023, an estimated $6.62K.
  • Ergoteles first reported a position in Spyre Therapeutics in Q2 2021 and held it in 3 quarters.
  • Ergoteles's Spyre Therapeutics position peaked at $237K in Q2 2021.
  • 44 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.